{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:15:17Z","timestamp":1785402917311,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.purol.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T18:09:09Z","timestamp":1340820549000},"page":"920-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie (CC-AFU) pour la bonne pratique des instillations endov\u00e9sicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n\u2019envahissant pas le muscle (TVNIM)"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Roupr\u00eat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Coloby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"R\u00e9billard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mongiat-Artus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chartier-Kastler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2012.05.002_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0010","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S1166-7087(10)70043-9","article-title":"Recommandations en onco-urologie 2010\u00a0: tumeurs uroth\u00e9liales","volume":"20","author":"Pfister","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011\u00a0update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2009.06.009","article-title":"Traitement par instillations v\u00e9sicales de BCG et mitomycine C dans les tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: enqu\u00eate de pratique de l\u2019AFU aupr\u00e8s des urologues francais","volume":"19","author":"Descazeaud","year":"2009","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0025","first-page":"1067","article-title":"Immunoth\u00e9rapie endov\u00e9sicale\u00a0: le bacille de Calmette-Guerin","volume":"11","author":"Chopin","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0030","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.purol.2012.05.002_bib0035","first-page":"22","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1\u00a0bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2010.12.002","article-title":"Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0055","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of non-muscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.purol.2012.05.002_bib0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0075","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1\u00a0and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0080","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1166-7087(10)70025-7","article-title":"Les vraies contre-indications du BCG dans le traitement des tumeurs de vessie","volume":"20","author":"Neuzillet","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.purol.2012.05.002_bib0090","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0022-5347(17)38154-5","article-title":"Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy","volume":"146","author":"Pisters","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2004.07.027","article-title":"Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma","volume":"65","author":"Falkensammer","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.05.002_bib0100","first-page":"335","article-title":"Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602\u00a0patients and comparison of chemotherapy complications","volume":"310","author":"Lamm","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.purol.2012.05.002_bib0105","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0022-5347(05)67025-5","article-title":"Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin","volume":"164","author":"Leibovici","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-004-1063-8","article-title":"Reactive arthritis following BCG immunotherapy for bladder carcinoma","volume":"24","author":"Tinazzi","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.purol.2012.05.002_bib0115","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.05.002_bib0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2011.04.024","article-title":"Thirty-five years of intravesical bacillus Calmette-Guerin for bladder cancer: where now?","volume":"60","author":"Catto","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","article-title":"Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy","volume":"29","author":"Yates","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2012.05.002_bib0135","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01302-08","article-title":"Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics","volume":"53","author":"Ritz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.purol.2012.05.002_bib0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.05.002_bib0150","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708712001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708712001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:22:12Z","timestamp":1761114132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708712001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1166708712001492"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2012.05.002","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie (CC-AFU) pour la bonne pratique des instillations endov\u00e9sicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n\u2019envahissant pas le muscle (TVNIM)","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}